Press Releases Items Per Page 102550 Year None202020192018 11-24-2020 Akero Therapeutics to Present at Evercore ISI 3rd Annual HealthCONx Virtual Conference 11-13-2020 Akero Presents Additional Positive Data from Phase 2a BALANCED Study Demonstrating Potential of Efruxifermin as a Foundational NASH Monotherapy 11-12-2020 Akero Therapeutics Reports Third Quarter 2020 Financial Results 10-21-2020 Akero Therapeutics To Present At Upcoming Conferences In November 10-16-2020 Akero Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for Efruxifermin (EFX) in NASH 10-02-2020 Akero Therapeutics To Present Data From Phase 2a BALANCED Study Of Efruxifermin In NASH Patients In Presidential Plenary Talk At The Liver Meeting® 2020 09-30-2020 Akero Therapeutics Completes Enrollment of Cohort of Cirrhotic (F4) Patients In Ongoing Balanced Study 09-28-2020 Akero Therapeutics to Present at H.C. Wainwright's 4th Annual NASH Virtual Investor Conference 09-24-2020 Akero Therapeutics To Continue Efruxifermin Development With Innovative Adaptive Phase 2b/3 Clinical Trial Design Based On FDA Written Guidance 09-09-2020 Akero Therapeutics To Present At Morgan Stanley's 18th Annual Global Healthcare Conference Pagination Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 26
11-13-2020 Akero Presents Additional Positive Data from Phase 2a BALANCED Study Demonstrating Potential of Efruxifermin as a Foundational NASH Monotherapy
10-16-2020 Akero Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for Efruxifermin (EFX) in NASH
10-02-2020 Akero Therapeutics To Present Data From Phase 2a BALANCED Study Of Efruxifermin In NASH Patients In Presidential Plenary Talk At The Liver Meeting® 2020
09-30-2020 Akero Therapeutics Completes Enrollment of Cohort of Cirrhotic (F4) Patients In Ongoing Balanced Study
09-28-2020 Akero Therapeutics to Present at H.C. Wainwright's 4th Annual NASH Virtual Investor Conference
09-24-2020 Akero Therapeutics To Continue Efruxifermin Development With Innovative Adaptive Phase 2b/3 Clinical Trial Design Based On FDA Written Guidance
09-09-2020 Akero Therapeutics To Present At Morgan Stanley's 18th Annual Global Healthcare Conference
